HUT70399A - Quinoline derivatives of mostly leukotriene antagonistic activity and pharmaceutical compositions comprising them - Google Patents

Quinoline derivatives of mostly leukotriene antagonistic activity and pharmaceutical compositions comprising them

Info

Publication number
HUT70399A
HUT70399A HU9402905A HU9402905A HUT70399A HU T70399 A HUT70399 A HU T70399A HU 9402905 A HU9402905 A HU 9402905A HU 9402905 A HU9402905 A HU 9402905A HU T70399 A HUT70399 A HU T70399A
Authority
HU
Hungary
Prior art keywords
mostly
pharmaceutical compositions
antagonistic activity
quinoline derivatives
leukotriene
Prior art date
Application number
HU9402905A
Other languages
English (en)
Other versions
HU218917B (hu
HU9402905D0 (en
Inventor
Robert Zamboni
Marc Labelle
Daniel Guay
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of HU9402905D0 publication Critical patent/HU9402905D0/hu
Publication of HUT70399A publication Critical patent/HUT70399A/hu
Publication of HU218917B publication Critical patent/HU218917B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU9402905A 1992-04-10 1993-04-08 Leukotrién-antagonista hatású kinolinszármazékok és az ezeket tartalmazó gyógyászati készítmények, valamint eljárás a kinolinszármazékok előállítására HU218917B (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/866,690 US5270324A (en) 1992-04-10 1992-04-10 Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
CN92105948A CN1080169A (zh) 1992-04-10 1992-06-16 含有水溶性药物的控释片

Publications (3)

Publication Number Publication Date
HU9402905D0 HU9402905D0 (en) 1995-01-30
HUT70399A true HUT70399A (en) 1995-10-30
HU218917B HU218917B (hu) 2000-12-28

Family

ID=25742768

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9402905A HU218917B (hu) 1992-04-10 1993-04-08 Leukotrién-antagonista hatású kinolinszármazékok és az ezeket tartalmazó gyógyászati készítmények, valamint eljárás a kinolinszármazékok előállítására

Country Status (21)

Country Link
US (1) US5270324A (hu)
EP (1) EP0565185B1 (hu)
JP (1) JP2504687B2 (hu)
CN (2) CN1080169A (hu)
AT (1) ATE168100T1 (hu)
AU (1) AU653476B2 (hu)
BG (1) BG62402B1 (hu)
CA (1) CA2092896C (hu)
CZ (1) CZ246394A3 (hu)
DE (1) DE69319482T2 (hu)
ES (1) ES2117691T3 (hu)
FI (1) FI944734A0 (hu)
HR (1) HRP930803A2 (hu)
HU (1) HU218917B (hu)
IL (1) IL105193A0 (hu)
LV (1) LV12290B (hu)
MX (1) MX9302033A (hu)
NO (1) NO943792L (hu)
SI (1) SI9300188A (hu)
WO (1) WO1993021159A1 (hu)
ZA (1) ZA932533B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
GB9216768D0 (en) * 1992-08-07 1992-09-23 Leo Pharm Prod Ltd Chemical compounds
ES2080656B1 (es) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
CA2130723C (en) * 1993-09-03 2006-01-31 Wilhelm Quittmann Process for preparing y-mercaptocarboxylic acid derivatives
DE4339724C1 (de) * 1993-11-22 1995-01-19 Siemens Ag Gasarmatur
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5427933A (en) * 1994-07-20 1995-06-27 Merck & Co., Inc. Reduction of phenylalkyl ketones to the corresponding (S)-hydroxy derivatives using mucor hiemalis IFO 5834
US5491077A (en) * 1994-07-20 1996-02-13 Merck & Co., Inc. Microbial method
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
US5545758A (en) * 1994-08-11 1996-08-13 Merck & Co., Inc. Process for the preparation of diisopinocampheylchloroborane
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5648448A (en) * 1995-06-06 1997-07-15 Hitachi Chemical Company, Ltd. Method of preparation of polyquinolines
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
JPH11504044A (ja) * 1996-02-08 1999-04-06 メルク エンド カンパニー インコーポレーテッド 治療方法及び医薬製剤
IL136461A0 (en) * 1997-12-23 2001-06-14 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6696466B1 (en) * 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
CA2371048C (en) 2002-02-06 2011-01-04 Delmar Chemicals Inc. Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
DE50307710D1 (de) * 2003-08-15 2007-08-30 Abb Turbo Systems Ag Rotationsdichtung
ES2371549T3 (es) * 2003-10-10 2012-01-05 Synthon B.V. Montelukast en estado sólido.
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
CA2575932A1 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
CA2585122A1 (en) 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
CN101426767A (zh) * 2005-11-16 2009-05-06 特瓦制药工业有限公司 经共沸除去溶剂的孟鲁司特钠干燥方法
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
CN101432267A (zh) * 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
US20090326232A1 (en) * 2006-06-26 2009-12-31 Uttam Kumar Ray Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)
SG173366A1 (en) * 2006-07-11 2011-08-29 Schering Corp Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
PL205444B1 (pl) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
EP2265586A4 (en) * 2008-03-17 2012-10-03 Reddys Lab Ltd Dr PREPARATION OF MONTELUKAST AND ITS SALTS
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
AR077101A1 (es) 2009-06-16 2011-08-03 Schering Corp Esteroides de heteroarilo (3,2-c), como agonistas de receptor glucocorticoide, composiciones y usos de los mismos
JP6038914B2 (ja) * 2011-07-26 2016-12-07 スン プハルマ アドバンセド リサーチ カンパニー リミテド キノリン−、キノキサリン、又はベンゾチアゾールベースのシステイニルロイコトリエンアンタゴニスト（ｌｔｃ４）
CN104069502B (zh) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
CN105085391B (zh) 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK282986A (da) * 1985-06-18 1987-02-24 Merck Frosst Canada Inc Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
US4962203A (en) * 1985-06-18 1990-10-09 Merck Frost Canada, Inc. 2-substituted quinolines useful as leukotriene antagonists
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
FR2617352B1 (fr) * 1987-06-26 1989-12-01 Eduvision Sa Procede de codage de donnees informatiques pour transmission aux normes video, videodisque mettant en oeuvre ledit procede et interface d'exploitation d'un tel videodisque
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
DE3814504A1 (de) * 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3900261A1 (de) * 1988-05-31 1989-12-07 Bayer Ag Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
CA2053209C (en) * 1990-10-12 1998-12-08 Michel L. Belley Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists

Also Published As

Publication number Publication date
DE69319482T2 (de) 1999-02-04
HRP930803A2 (en) 1994-12-31
IL105193A0 (en) 1993-07-08
AU3686393A (en) 1993-10-14
LV12290B (en) 1999-11-20
DE69319482D1 (de) 1998-08-13
AU653476B2 (en) 1994-09-29
CA2092896C (en) 2005-12-20
ZA932533B (en) 1993-11-04
EP0565185A1 (en) 1993-10-13
HU218917B (hu) 2000-12-28
NO943792L (no) 1994-12-08
BG62402B1 (bg) 1999-10-29
CN1043761C (zh) 1999-06-23
MX9302033A (es) 1994-07-29
FI944734A (fi) 1994-10-07
ES2117691T3 (es) 1998-08-16
JP2504687B2 (ja) 1996-06-05
HU9402905D0 (en) 1995-01-30
CA2092896A1 (en) 1993-10-11
US5270324A (en) 1993-12-14
ATE168100T1 (de) 1998-07-15
CZ246394A3 (en) 1996-01-17
SI9300188A (sl) 1993-12-31
WO1993021159A1 (en) 1993-10-28
EP0565185B1 (en) 1998-07-08
JPH0625173A (ja) 1994-02-01
CN1083052A (zh) 1994-03-02
BG99085A (bg) 1995-06-30
FI944734A0 (fi) 1994-10-07
CN1080169A (zh) 1994-01-05
LV12290A (lv) 1999-06-20
NO943792D0 (no) 1994-10-07

Similar Documents

Publication Publication Date Title
HUT70399A (en) Quinoline derivatives of mostly leukotriene antagonistic activity and pharmaceutical compositions comprising them
LV12187A (lv) Nepiesatinatas hidroksialkiletas hinolina rindas karbonskabes
IL100985A0 (en) Quinoline-containing ketoacids and pharmaceutical compositions containing them
PL309408A1 (en) Diaryl-5,6-condensed heterocyclic acids as leucotrenic antagonistic substances
AU639612B2 (en) Hydroxyalkylquinoline ether acids as leukotriene antagonists
MY107767A (en) Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: MERCK FROSST CANADA & CO., CA

HMM4 Cancellation of final prot. due to non-payment of fee